Pacific Biosciences of California Inc. buy UBS Group AG
Start price
16.02.24
/
50%
€5.53
Target price
16.02.25
€11.13
Performance (%)
-67.79%
End price
17.02.25
€1.78
Summary
This prediction ended on 17.02.25 with a price of €1.78. Massive losses of -67.79% were the result for the BUY prediction by UBS_Group_AG. UBS_Group_AG has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y |
|---|---|---|---|
| Pacific Biosciences of California Inc. | -4.492% | -4.492% | 10.340% |
| iShares Core DAX® | 1.604% | -7.448% | 3.039% |
| iShares Nasdaq 100 | -0.734% | -1.864% | 15.425% |
| iShares Nikkei 225® | 1.296% | -6.795% | 34.306% |
| iShares S&P 500 | -0.394% | -2.336% | 9.907% |
Comments by UBS_Group_AG for this prediction
In the thread Pacific Biosciences of California Inc. diskutieren
Pacific Biosciences of California, Inc. (NASDAQ: PACB) had its price target lowered by analysts at UBS Group AG from $12.50 to $12.00. They now have a "buy" rating on the stock.
Ratings data for PACB provided by MarketBeat
In the thread Trading Pacific Biosciences of California Inc.
Die von UBS_Group_AG gewählte maximale Laufzeit wurde überschritten
Stopped prediction by UBS_Group_AG for Pacific Biosciences of California Inc.
Pacific Biosciences of California Inc.
Start price
Target price
Perf. (%)
€7.17
17.11.23
17.11.23
€9.20
17.11.24
17.11.24
-79.08%
18.11.24
18.11.24
